MET is required for the recruitment of anti-tumoural neutrophils
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Mutations or amplification of the MET proto-oncogene are involved in the pathogenesis of several tumours, which rely on the constitutive engagement of this pathway for their growth and survival. However, MET is expressed not only by cancer cells but also by tumour-associated stromal cells, although its precise role in this compartment is not well characterized. Here we show that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor (HGF). Met deletion in mouse neutrophils enhances tumour growth and metastasis. This phenotype correlates with reduced neutrophil infiltration to both the primary tumour and metastatic sites. Similarly, Met is necessary for neutrophil transudation during colitis, skin rash or peritonitis. Mechanistically, Met is induced by tumour-derived tumour necrosis factor (TNF)-α or other inflammatory stimuli in both mouse and human neutrophils. This induction is instrumental for neutrophil transmigration across an activated endothelium and for inducible nitric oxide synthase production upon HGF stimulation. Consequently, HGF/MET-dependent nitric oxide release by neutrophils promotes cancer cell killing, which abates tumour growth and metastasis. After systemic administration of a MET kinase inhibitor, we prove that the therapeutic benefit of MET targeting in cancer cells is partly countered by the pro-tumoural effect arising from MET blockade in neutrophils. Our work identifies an unprecedented role of MET in neutrophils, suggests a potential ‘Achilles’ heel’ of MET-targeted therapies in cancer, and supports the rationale for evaluating anti-MET drugs in certain inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIF-1α is essential for myeloid cell-mediated inflammation
Cramer, T., Yamanishi, Y., Clausen, B. E., Förster, I., Pawlinski, R., Mackman, N., Haase, V. H., Jaenisch, R., Corr, M., Nizet, V., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00154-5 · Cited by 2,046
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Bussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., & Comoglio, P. M. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.629 · Cited by 1,337
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Self-citationDrug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Haslett, C., Guthrie, L. A., Kopaniak, M. M., Johnston, R. B., & Henson, P. M. (1985) · PubMed Central · Cited by 779
Neutrophil function in inflammation and inflammatory diseases
Wright, H. L., Moots, R. J., Bucknall, R. C., & Edwards, S. W. (2010) · Rheumatology · doi:10.1093/rheumatology/keq045 · Cited by 761
Tumor-associated neutrophils: friend or foe?
Fridlender, Z. G., & Albelda, S. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs123 · Cited by 699
Neufert, C., Becker, C., & Neurath, M. F. (2007) · Nature Protocols · doi:10.1038/nprot.2007.279 · Cited by 675
Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3383 · Cited by 463
Cited by
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Neutrophils support lung colonization of metastasis-initiating breast cancer cells
Wculek, S. K., & Malanchi, I. (2015) · Nature · doi:10.1038/nature16140 · Cited by 1,003
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Teijeira, Á., Garasa, S., Gato, M., Alfaro, C., Migueliz, I., Cirella, A., de Andrea, C., Ochoa, M. C., Otano, I., Etxeberria, I., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.001 · Cited by 788
Neutrophil plasticity in the tumor microenvironment
Giese, M. A., Hind, L. E., & Huttenlocher, A. (2019) · Blood · doi:10.1182/blood-2018-11-844548 · Cited by 783
Neutrophils in cancer: heterogeneous and multifaceted
Hedrick, C. C., & Malanchi, I. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00571-6 · Cited by 768
Neutrophils as emerging therapeutic targets
Németh, T., Sperandio, M., & Mócsai, A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0054-z · Cited by 653
Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy
Masucci, M. T., Minopoli, M., & Carriero, M. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01146 · Cited by 649
Xiao, Y., Cong, M., Li, J., He, D., Wu, Q., Tian, P., Wang, Y., Yang, S., Liang, C., Liang, Y., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.012 · Cited by 649
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589
Neutrophils in the tumor microenvironment
Powell, D. R., & Huttenlocher, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.11.008 · Cited by 578
“Interestingly, HGF signaling through the Met receptor also can recruit neutrophils that have anti-tumor effects [67] suggesting a potential feedback loop mediated by HGF signaling.”
BackgroundNeutrophils in cancer carcinogenesis and metastasis
Xiong, S., Dong, L., & Cheng, L. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01187-y · Cited by 564
Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis
Wenes, M., Shang, M., Di Matteo, M., Goveia, J., Martín-Pérez, R., Serneels, J., Prenen, H., Ghesquière, B., Carmeliet, P., & Mazzone, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.008 · Cited by 496
Self-citationNeutrophils in cancer: prognostic role and therapeutic strategies
Ocana, A., Nieto-Jiménez, C., Pandiella, A., & Templeton, A. J. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0707-7 · Cited by 459
Neutrophil heterogeneity: implications for homeostasis and pathogenesis
Silvestre-Roig, C., Hidalgo, A., & Soehnlein, O. (2016) · Blood · doi:10.1182/blood-2016-01-688887 · Cited by 450
Palmieri, E. M., Menga, A., Martín-Pérez, R., Quinto, A., Riera-Domingo, C., De Tullio, G., Hooper, D. C., Lamers, W. H., Ghesquière, B., McVicar, D. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.054 · Cited by 404
Self-citationNeutrophils in Homeostasis, Immunity, and Cancer
Nicolás-Ávila, J. Á., Adrover, J. M., & Hidalgo, A. (2017) · Immunity · doi:10.1016/j.immuni.2016.12.012 · Cited by 403
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Comoglio, P. M., Trusolino, L., & Boccaccio, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0002-y · Cited by 381
Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis
Cui, C., Chakraborty, K., Tang, X. A., Zhou, G., Schoenfelt, K. Q., Becker, K. M., Hoffman, A., Chang, Y.-F., Blank, A., Reardon, C. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.016 · Cited by 364
Neutrophil Degranulation, Plasticity, and Cancer Metastasis
Mollinedo, F. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.006 · Cited by 353
The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis
Liang, W., & Ferrara, N. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0313 · Cited by 347
Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
Zhou, J., Nefedova, Y., Lei, A., & Gabrilovich, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2017.12.004 · Cited by 339
Tumor-Associated Neutrophils in Cancer: Going Pro
Wu, L., Saxena, S., Awaji, M., & Singh, R. K. (2019) · Cancers · doi:10.3390/cancers11040564 · Cited by 337
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 312
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Self-citationT cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants
Hirschhorn, D., Budhu, S., Kraehenbuehl, L., Gigoux, M., Schröder, D., Chow, A., Ricca, J. M., Gasmi, B., De Henau, O., Mangarin, L. M. B., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.007 · Cited by 303
Glodde, N., Bald, T., van den Boorn-Konijnenberg, D., Nakamura, K., O’Donnell, J. S., Szczepanski, S., Brandes, M., Eickhoff, S., Das, I., Shridhar, N., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.012 · Cited by 277
Self-citationIL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy
Teijeira, A., Garasa, S., Ochoa, M. C., Villalba, M., Olivera, I., Cirella, A., Eguren-Santamaria, I., Berraondo, P., Schalper, K. A., de Andrea, C. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1319 · Cited by 268
Ponzetta, A., Carriero, R., Carnevale, S., Barbagallo, M., Molgora, M., Perucchini, C., Magrini, E., Gianni, F., Kunderfranco, P., Polentarutti, N., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.047 · Cited by 255
Neutrophil diversity and function in health and disease
Zhang, F., Xia, Y., Su, J., Quan, F., Zhou, H., Li, Q., Feng, Q., Lin, C., Wang, D., & Jiang, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02049-y · Cited by 246
Hypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
“PMNs expressing the hepatocyte growth factor (HGF) receptor, c-MET, were found to be antitumorigenic in mouse models of colon cancer and liver cancer (90).”
BackgroundLy6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164
Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments
Janiszewska, M., Tabassum, D. P., Castaño, Z., Cristea, S., Yamamoto, K. N., Kingston, N. L., Murphy, K. C., Shu, S., Harper, N. W., Del Alcazar, C. G., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0346-x · Cited by 159
Garg, A. D., Vandenberk, L., Fang, S., Fasche, T., Van Eygen, S., Maes, J., Van Woensel, M., Koks, C., Vanthillo, N., Graf, N., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.15 · Cited by 120
“, H2O2-/NO-based, typically against pathogens).(12,26,30,31) Neutrophils interacting with MTXinduced dying cells did not appreciably upregulate FasL/ perforins (Supplementary Figures S10A and B); however, they significantly released H2O2 and NO (Figure 6n).”
BackgroundHGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113595 · Cited by 110
“Indeed, this mechanism could represent an escape from tumor killing upon MET-inhibitor treatment, a th y lso block the kinase activity in neutrophils [55].”
BackgroundRecent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology
László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., & Vas, V. (2021) · Cells · doi:10.3390/cells10030667 · Cited by 58
Kato, T. (2017) · Biomedical Reports · doi:10.3892/br.2017.1001 · Cited by 49
“The HGF-Met system is also required for neutrophil chemoattraction and cytotoxicity, and Met deletion in neutrophils enhances tumor growth and metastasis (43).”
Phan, Q. T., Solis, N. V., Cravener, M. V., Swidergall, M., Lin, J., Huang, M. Y., Liu, H., Singh, S., Ibrahim, A. S., Mazzone, M., et al. (2023) · PLOS Pathogens · doi:10.1371/journal.ppat.1011579 · Cited by 29
“To determine if Hyr1 influences susceptibility to neutrophil killing by interacting with c-Met, we tested neutrophils from Mrp8; Met fl/fl mice, which have a neutrophil-specific deletion in c-Met [30].”
Self-citationLiu, T. W., Gammon, S. T., Yang, P., Fuentes, D., & Piwnica-Worms, D. (2021) · Science Signaling · doi:10.1126/scisignal.aax5971 · Cited by 27
Zhao, D., Li, H., Mambetsariev, I., Mirzapoiazova, T., Chen, C., Fricke, J., Kulkarni, P., Villaflor, V., Arvanitis, L., Hamilton, S., et al. (2022) · Cancers · doi:10.3390/cancers14194933 · Cited by 24
Determinants, mechanisms, and functional outcomes of myeloid cell diversity in cancer
Caronni, N., Montaldo, E., Mezzanzanica, L., Cilenti, F., Genua, M., & Ostuni, R. (2021) · Immunological Reviews · doi:10.1111/imr.12944 · Cited by 6
Metadata
- Authors
- Finisguerra, V., Di Conza, G., Di Matteo, M., Serneels, J., Costa, S., Thompson, A. A. R., Wauters, E., Walmsley, S., Prenen, H., Granot, Z., Casazza, A., & Mazzone, M.
- Venue
- Nature
- Published
- 2015-05-18
- Volume
- 522
- Issue
- 7556
- Pages
- 349-353
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1920052832
- Cited by
- 492
- References
- 36
- FWCI
- 14.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.